| P/E (FY) | 20.5 | Sales (TTM) | €338.9M |
| Earnings (TTM) | €10.4M | ROE | 4.96% |
| Net Margin | 3.06% | ROIC | 5.55% |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | 22.92% | Sales Growth 3Y | 12.78% |
Laboratorio Reig Jofre, S.A. is a pharmaceutical company that researches, develops, manufactures, and markets pharmaceutical products, raw materials, biotechnological products, nutritional supplements, medical devices, cosmetics, and related goods. Its offerings include antibiotics and injectables, specialty pharmacare products for skin, hair, nails, joints, and women's health, and food supplements under the Forté Pharma brand, alongside CDMO and CMO services. Founded in 1929, it is headquartered in Barcelona and operates as a subsidiary of Reig Jofre Investments SL.
| Market Cap | $214.4M | Trading Days | 4188 |
| 52W High | 3.35 |
| 52W Low | 2.32 |
| % Off High | −20.60% |
| YTD | 4.42% | 1Y | −8.41% |
| 3Y | −1.34% | 5Y | −44.61% |
| 10Y | −4.06% | Since incept. (ann.) | −7.21% |
| Ann. Volatility (1Y) | 23.02% | Ann. Volatility (3Y) | 27.95% |
| Sharpe (1Y) | −0.27 | Sharpe (3Y) | 0.08 |
| Max Drawdown (1Y) | −27.19% | Max Drawdown (3Y) | −29.18% |
| Beta (3Y, vs SPY) | 0.62 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| TARA | Protara Therapeutics, Inc. | $214.7M | — |
| EMBC | Embecta Corp. | $213.0M | 2.2 |
| BDSX | BIODESIX INC | $212.6M | — |
| EPRX | EUPRAXIA PHARMACEUTICALS INC. | $217.4M | — |
| ATRY.MC | ATRYS HEALTH, S.A. | $218.6M | — |
| BCAB | BioAtla, Inc. | $207.7M | — |
| CHRS | Coherus Oncology, Inc. | $222.1M | 1.0 |
| SGMT | Sagimet Biosciences Inc. | $223.0M | — |
| GALT | GALECTIN THERAPEUTICS INC | $223.3M | — |
| TNG.PA | TRANSGENE | $224.7M | — |
| RNAC | Cartesian Therapeutics, Inc. | $224.8M | — |
| SRZN | Surrozen, Inc./DE | $225.2M | — |
